

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier

Zhihao Lu,¹ Huan Chen,² Xi Jiao,¹ Wei Zhou,² Wenbo Han,² Shuang Li,¹ Chang Liu,¹ Jifang Gong,¹ Jian Li,¹ Xiaotian Zhang,¹ Xicheng Wang,¹ Zhi Peng,¹ Changsong Qi,¹ Zhenghang Wang,¹ Yanyan Li,¹ Jie Li,¹ Yan Li,¹ Malcolm Brock,³ Henghui Zhang,⁴ Lin Shen ¹

To cite: Lu Z, Chen H, Jiao X, *et al.* Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier. *Journal for ImmunoTherapy of Cancer* 2020;**8**:e000631. doi:10.1136/jitc-2020-000631

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jitc-2020-000631>).

ZL, HC and XJ contributed equally.

Accepted 22 July 2020



© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Professor Lin Shen, Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China; shenlin@bjmu.edu.cn

Dr Henghui Zhang, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China; zhhbao@ccmu.edu.cn

ABSTRACT

Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of gastrointestinal cancer. However, biomarkers correlated with the efficacy of ICIs in gastrointestinal cancer are still lacking. In this study, we performed 395-plex immune oncology (IO)-related gene target sequencing in tumor samples from 96 patients with metastatic gastrointestinal cancer patients treated with ICIs, and a linear support vector machine learning strategy was applied to construct a predictive model. Results All 96 patients were randomly assigned into the discovery (n=72) and validation (n=24) cohorts. A 24-gene RNA signature (termed the IO-score) was constructed from 395 immune-related gene expression profiling using a machine learning strategy to identify patients who might benefit from ICIs. The durable clinical benefit rate was higher in patients with a high IO-score than in patients with a low IO-score (discovery cohort: 92.0% vs 4.3%, p<0.001; validation cohort: 85.7% vs 17.6%, p=0.004). The IO-score may exhibit a higher predictive value in the discovery (area under the receiver operating characteristic curve (AUC)=0.97) and validation (AUC=0.74) cohorts compared with the programmed death ligand 1 positivity (AUC=0.52), tumor mutational burden (AUC=0.69) and microsatellite instability status (AUC=0.59) in the combined cohort. Moreover, patients with a high IO-score also exhibited a prolonged overall survival compared with patients with a low IO-score (discovery cohort: HR, 0.29; 95% CI 0.15 to 0.56; p=0.003; validation cohort: HR, 0.32; 95% CI 0.10 to 1.05; p=0.04). Taken together, our results indicated the potential of IO-score as a biomarker for immunotherapy in patients with gastrointestinal cancers.

INTRODUCTION

Immune checkpoint inhibitors (ICIs) have made remarkable achievements in the treatment of cancer, including gastrointestinal (GI) cancers. However, the objective response rate of patients with GI cancers to ICIs was only 10%–20%, underscoring the need for

effective biomarker-based patient selection.¹ To date, the predictive biomarkers used to guide patient selection mainly fall into two categories: those reflecting tumor intrinsic properties, such as the microsatellite instability (MSI)/mismatch repair (MMR) status and a high tumor mutational burden (TMB) and those associated with the tumor microenvironment (TME), such as programmed death ligand 1 (PD-L1) expression and immune-related RNA expression.^{2,3} However, previous studies have reported conflicting results regarding the association of those biomarkers with ICI efficacy in GI cancers,^{4–7} emphasizing the urgent need to explore new optimal predictors. Here, we applied a 395-plex immune oncology (IO)-related gene profiling platform and machine learning strategy to determine a novel RNA signature that may reflect the ‘immune-responsive feature’ of both cancer cells and the immune microenvironment.

METHODS

Patients

Patients with metastatic GI cancers who failed standard therapy and had received anti-programmed cell death 1 (PD-1)/PD-L1 therapy or in combination with a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor between January 2016 and January 2018 were recruited. The tumor response was measured by imaging studies or physical examinations according to the Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and iRECIST. Durable clinical benefit (DCB) was defined

as complete response, partial response, or stable disease (SD) lasting for ≥ 24 weeks, and no durable benefit (NDB) was defined as progressive disease or SD that lasted for < 24 weeks.⁸

Gene expression profiling

Total RNA was isolated from 5 μm thick pretreatment archival formalin-fixed, paraffin-embedded (FFPE) sections of tumors. Gene expression profiling was performed using a panel sequencing platform that determines the expression of 395 human genes belonging to the following functional categories⁹: immunological response to immunotherapy, infiltrating immune cell markers, tumor-specific antigens, tumor markers and essential signaling pathways. Detailed information on the RNA profiling method and the data processing pipeline is provided in the online supplementary methods.

Construction of a linear support vector machine classifier

In the discovery cohort, the linear support vector machine (linear SVM) model was applied to distinguish 25 individuals with DCB from 47 patients with NDB based on the 395-gene RNA profiling data (online supplementary methods). Briefly, after data standardization and normalization, recursive feature elimination with cross-validation was performed to select features. We used the sigmoid function to scale the distance to the SVM classifier boundary into the range [0–1], which was designated as the IO-score. The prediction of the independent validation cohort was generated with the training test set procedure. The area under the receiver operating characteristic curve (AUC) was then calculated from the IO-score and the binary group labels (DCB and NDB). We used the Youden index as the cut-off point (high IO-score > 0.52) to stratify patients with different prognoses and DCB rates.

Evaluation of TMB

We extracted genomic DNA from FFPE specimens and matched white blood cell samples using the blackPREP FFPE DNA Kit (Analytik Jena AG, Jena, Germany) and the Tiangen Whole Blood DNA Kit (Tiangen, Beijing, PRC) according to the manufacturer's instructions. Whole exome sequencing was then performed to detect genomic alterations. The TMB was determined by analyzing the number of somatic mutations per megabase (mb). The cut-off value for TMB-high and TMB-low was defined as 5 mutations/mb as previously reported.¹⁰

Immunohistochemical staining for PD-L1

PD-L1 status was assessed by immunohistochemical (IHC)-stained archival FFPE sections using an anti-PD-L1 (rabbit, clone SP142, 1:100; Spring Bioscience, California, USA) antibody. PD-L1 expression was evaluated in tumor cells and tumor-infiltrating immune cells. PD-L1 positivity was defined as $\geq 1\%$ of the tumor/stromal cell membrane staining.

Assessing the MSI/MMR status

To determine the MMR status, IHC was performed on archival FFPE sections using monoclonal anti-mutL homolog 1, anti-mutS homolog 2, anti-mutS homolog 6 and PMS1 homolog 2. Tumors lacking expression of any one of the four proteins were considered deficient MMR (dMMR); otherwise, they were considered proficient MMR (pMMR). In some cases, to determine MSI status, PCR-based molecular testing was employed, which assesses five microsatellite loci comprising BAT-25, BAT-26, D2S123, D5S346, and D17S250.^{11 12} MSI-high (MSI-H) tumors were defined as instability at two or more of these markers, whereas MSI-low and microsatellite stability (MSS) were defined as instability at a single locus and no instability at any locus, respectively.¹³

Statistical analysis

Statistical tests included the χ^2 test, Student's t-test and the Mann-Whitney U test. A receiver operating characteristic curve was generated to evaluate the diagnostic accuracy. The AUC was calculated to measure the discriminatory ability of the potential biomarkers. Progression-free survival (PFS) and overall survival (OS) were analyzed with the Kaplan-Meier method and log-rank test.

RESULTS

Patient characteristics

A total of 96 patients with metastatic GI cancers were randomly assigned into a discovery cohort ($n=72$) and a validation cohort ($n=24$; figure 1A). Clinical characteristics of the subjects are summarized in online supplementary table S1. All patients had received anti-PD-1/anti-PD-L1 therapy or in combination with anti-CTLA4 antibodies. The clinical end points include OS and PFS, and the therapeutic response.

Model construction and performance evaluation of the linear SVM-derived IO-score

Based on the expression levels of 395-genes in patients with DCB and NDB in the discovery cohort, a linear SVM classification algorithm was adopted to construct a prediction model (figure 1A and online supplementary figure S1). The best-performing features and hyperparameters were determined by 13-fold cross-validation within the discovery cohort. Intriguingly, a linear SVM classifier composed of 24 IO-related genes was developed, and the IO-score of each sample was subsequently derived (figure 1B and online supplementary table S2).

The performance of the IO-score was comprehensively evaluated, and overall accuracies of 94% and 83% were achieved for discriminating DCB and NDB in the discovery (AUC=0.97; 95% CI 0.93 to 1.00) and validation (AUC=0.74; 95% CI 0.51 to 0.97) cohorts, respectively (figure 2A and online supplementary table S3). Moreover, a higher DCB rate was observed in patients with a high IO-score than in patients with a low IO-score (discovery cohort: 92.0% (23 of 25) vs 4.3% (2 of 47),




Figure 1 Flow diagram of the machine learning strategy and IO-score composition. (A), Flow diagram of the construction of the linear SVM classifier construction. (B), Feature importance of the linear SVM-classifier-derived 24-gene RNA signature, namely, the IO-score. DCB, durable clinical benefit; ICI, immune checkpoint inhibitor; IO, immune oncology; NDB, no durable benefit; nRPM, normalized reads per million; SVM, support vector machine.

$p < 0.001$; validation cohort: 85.7% (6 of 7) vs 17.6% (3 of 17), $p = 0.004$, **figure 2B**). Furthermore, a favorable prognosis was identified in the high IO-score subgroup when compared with that in the low IO-score subgroup (**figure 2C–D**).

Predictive and prognostic values of the TMB, PD-L1 positivity and MSI/MMR status

We then evaluated the predictive and prognostic values of other candidate biomarkers in the combined cohort (online supplementary table S4 and online

supplementary figures S2–S4), with AUCs of 0.69 (95% CI 0.57 to 0.80), 0.59 (95% CI 0.45 to 0.73), and 0.52 (95% CI 0.37 to 0.67) for TMB, MSI/MMR, and PD-L1 positivity, respectively. As expected, a better prognosis was also identified in the TMB-high and MSI-H/dMMR subgroups than in the TMB-low and MSS/pMMR subgroups (online supplementary figures S2 and S3). However, the IO-score tended to have greater power for patient stratification, as revealed by the high odds ratio (OR) for DCB (**figure 3** and online supplementary table




Figure 2 Predictive and prognostic value of the IO-score in the discovery and validation cohorts. (A) ROC curve of the IO-score in predicting the clinical benefit. (B) Comparison of the DCB rates between the IO-score-high and IO-score-low groups. (C) and (D) Kaplan-Meier curves comparing PFS (C) and OS (D) between the IO-score-high and IO-score-low subgroups. AUC, area under the receiver operating characteristic curve; DCB, durable clinical benefit; IO, immune oncology; OS, overall survival; PFS, progression-free survival; ROC, receiver operating characteristic.




Figure 3 Forest plot showing the odds ratios (ORs) and 95% CIs for the associations of current biomarkers and DCB. DCB, durable clinical benefit; dMMR, deficient mismatch repair; IO, immune oncology; MSI, microsatellite instability; MSS, microsatellite stability; PD-L1, programmed death ligand 1; pMMR, proficient mismatch repair; TMB, tumor mutational burden.

S4) and the low HR of the survival analysis (figure 2C and D).

Notably, the waterfall plot of maximal tumor reduction in the two independent cohorts also sustained the superiority of the IO-score predictive model based on the IO-score (figure 4A and B). Furthermore, we analyzed the relationship between the IO-score and other potential biomarkers in the subgroup with a complete data set (n=52). Higher percentages of MSI-H and/or TMB-high patients were identified in the high IO-score subgroup

than in the low IO-score subgroup (online supplementary figure S5).

DISCUSSION

Based on our analysis, a linear SVM-derived RNA signature, the IO-score, may be a superior prognostic and predictive biomarker for GI cancer patients treated with ICIs. In previous studies, gene expression profile (GEP) signatures, such as the interferon- γ (IFN- γ) RNA signature and T-cell inflamed GEP, predict the efficacy of an anti-PD-1 treatment in patients with various tumor types, including head and neck squamous cell carcinoma and melanoma.^{2,3} However, data exploring the correlation between RNA signatures and GI cancers, particularly esophageal cancer and colorectal cancers, are still limited.¹⁴ Moreover, a prospective evaluation of the IFN- γ signature was performed in patients with gastric cancer,¹⁵ and the results showed that it failed to guide patient selection, possibly due to the great tumor heterogeneity and complexity of the TME.

Intriguingly, machine learning methodologies offer a novel approach for measuring the interactions between the tumor and the TME. Here, we used a state-of-the-art classification linear SVM strategy to construct a predictive model based on the IO-score. This novel RNA signature, the IO-score, comprises genes encoding tumor antigens, tumor suppressors/oncogenes, lymphocyte markers, interferons and checkpoint signaling pathways (online supplementary table S2 and online supplementary figure S6). This model may comprehensively capture the intrinsic pathological features of both tumor cells and infiltrating immune cells, which may partially explain the superiority of the IO-score compared with other predictors.

Conventionally, for clinical classification problems with a binary response, a logistic regression (LR) analysis is one of the most widely used models. Recently,




Figure 4 Waterfall plot of the response of patients with gastrointestinal cancers to ICIs. (A) Waterfall plot showing the candidate biomarkers in the discovery cohort. The Y-axis represents the percentage change in the summed longest diameters of the target lesions from baseline. (B) Waterfall plot showing the results for the validation cohort. dMMR, deficient mismatch repair; ICIs, immune checkpoint inhibitors; IO, immune oncology; MSI, microsatellite instability; MSS, microsatellite stability; PD-L1, programmed death ligand 1; pMMR, proficient mismatch repair; TMB, tumor mutational burden.

SVM became a relatively new alternative based on the principle of statistical learning theory to solve classification and regression problems.^{16–18} In terms of the algorithm, SVM has some unique advantages. For instance, the introduction of kernel function greatly simplifies the complexity of computation.¹⁷ SVMs also usually require fewer variables to achieve the same misclassification rate than LR, and it is possible to manage classification problem when the sample size is limited.¹⁹

Several limitations to the current study must be acknowledged. First, this was a retrospective study, and the predictive model may require further validation in a prospective study. Second, a larger cohort study would be helpful to optimize the cut-off value of the IO-score.

CONCLUSIONS

In summary, the IO-score, a machine learning-based RNA signature, effectively identifies the ‘immune responsive features’ of patients with GI cancers. The predictive model based on the IO-score exhibited superior predictive and prognostic value in both the discovery and validation cohorts and may help facilitate the individualized management of immunotherapy in patients with metastatic GI cancers.

Author affiliations

¹Department of Gastrointestinal Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

²Genecast Precision Medicine Technology Institute, Beijing, China

³Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

⁴Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China

Acknowledgements We thank a professional English-speaking editor (American Journal Experts) for assistance with improving the quality of the language.

Contributors LS and HZ designed the study. ZL, HC, and XJ wrote the manuscript. ZL, HC, XJ, WZ, WH, SL, CL, JG, JL, XZ, XW, ZP, CQ, ZW, YL, JL, and YL were involved in acquisition, analysis, and interpretation of data. ZL, HC, XJ, WZ, WH, HZ, LS, and MB provided critical revision of the manuscript for important intellectual content. HC, XJ, WZ, and WH performed statistical analyses. All authors read and approved the final manuscript.

Funding This work was supported by the National Key Research and Development Program of China (2017YFC1308900, 2018YFC1313302), the National Key Sci-Tech Special Project of China (2018ZX10302207), Beijing Hospitals Authority Youth Program (QML20191102), and the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (No. XXT19).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study was approved by the Medical Ethics Committee of Peking University Cancer Hospital & Institute.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. All data analyzed in our study are available upon request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which

permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iD

Lin Shen <http://orcid.org/0000-0003-1134-2922>

REFERENCES

- Akin Telli T, Bregni G, Camera S, *et al.* PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. *Cancer Lett* 2020;469:142–50.
- Ayers M, Lunceford J, Nebozhyn M, *et al.* IFN- γ -related mRNA profile predicts clinical response to PD-1 blockade. *J Clin Invest* 2017;127:2930–40.
- Cristescu R, Mogg R, Ayers M, *et al.* Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science* 2018;362:eaar3593.
- Wang F, Wei XL, Wang FH, *et al.* Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. *Ann Oncol* 2019;30:1479–86.
- Greally M, Chou JF, Chatila WK, *et al.* Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer. *Clin Cancer Res* 2018;25:6160–9.
- Huang J, Xu B, Mo H, *et al.* Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. *Clin Cancer Res* 2018;24:1296–304.
- Samstein RM, Lee C-H, Shoushtari AN, *et al.* Tumor mutational load predicts survival after immunotherapy across multiple cancer types. *Nat Genet* 2019;51:202–6.
- Rizvi NA, Hellmann MD, Snyder A, *et al.* Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science* 2015;348:124–8.
- Paluch BE, Glenn ST, Conroy JM, *et al.* Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. *Oncotarget* 2017;8:3197–205.
- Goodman AM, Kato S, Bazhenova L, *et al.* Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. *Mol Cancer Ther* 2017;16:2598–608.
- Boland CR, Thibodeau SN, Hamilton SR, *et al.* A national cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. *Cancer Res* 1998;58:5248–57.
- Luchini C, Bibeau F, Ligtenberg MJL, *et al.* ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. *Ann Oncol* 2019;30:1232–43.
- Suraweera N, Duval A, Reperant M, *et al.* Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. *Gastroenterology* 2002;123:1804–11.
- Doi T, Piha-Paul SA, Jalal SI, *et al.* Safety and antitumor activity of the Anti-Programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. *J Clin Oncol* 2018;36:61–7.
- Kelly RJ, Lee J, Bang Y-J, *et al.* Safety and efficacy of Durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma. *Clin Cancer Res* 2020;26:846–54.
- Jiang Y, Xie J, Han Z, *et al.* Immunomarker support vector machine classifier for prediction of gastric cancer survival and adjuvant chemotherapeutic benefit. *Clin Cancer Res* 2018;24:5574–84.
- Chen T, Zhang C, Liu Y, *et al.* A gastric cancer lncRNAs model for MSI and survival prediction based on support vector machine. *BMC Genomics* 2019;20:846.
- Harel M, Ortenberg R, Varanasi SK, *et al.* Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence. *Cell* 2019;179:e218:236–50.
- Verplancke T, Van Looy S, Benoit D, *et al.* Support vector machine versus logistic regression modeling for prediction of hospital mortality in critically ill patients with haematological malignancies. *BMC Med Inform Decis Mak* 2008;8:56.